Current Strategies and Future Perspective for the Effective Treatment of Diabetic Retinopathy-Reference-Cited by-同舟云学术

Current Strategies and Future Perspective for the Effective Treatment of Diabetic Retinopathy

Published:2020-11-30 Issue:4 Volume:15 Page:299-311
ISSN:1574-8855
Container-title:Current Drug Therapy
language:en
Short-container-title:CDTH

Author:

Sharma Deep Shikha¹,Singh Sachin Kumar¹,Thakur Divya²,K.R Arya¹,Khursheed Rubiya¹,Wadhwa Sheetu¹

Affiliation:

1. School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India

2. Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, Punjab, India

Abstract

Diabetes Retinopathy (DR) is one of the main complications due to diabetes. DR will damage the retinal capillaries and block them, which causes the loss of vision. Different drugs and therapies are used for the treatment and prevention of the DR. The most commonly used treatment is laser technology and combination therapy, along with some drugs. But these drugs possess side effects in the form of cataract, glaucoma, and complete blindness of the eye. The main strategy to overcome In DR, medicines with minimum side effects or maximum therapeutic effects are used. This article emphasizes the current strategy used for the treatment of DR with allopathic as well as herbal drugs.

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics

Reference81 articles.

1. IDF Diabetes Atlas ; Available from https://www.idf.org/e-library/epidemiology-research/diabetes-atlas.html(Accessed on April 24, 2018).

2. Wilkinson C.P.; Ferris F.L.; Klein R.E.; Global Diabetic Retinopathy Project Group Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003,110(9),1677-1682

3. Boles A.; Kandimalla R.; Reddy P.H.; Dynamics of diabetes and obesity: Epidemiological perspective. Biochim Biophys Acta Mol Basis Dis 2017,1863(5),1026-1036

4. NIH National Eye Institute Facts about diabetic eye disease Available from https://nei.nih.gov/health/diabetic/(Accessed on 2015)

5. Kim J.H.; Kim J.H.; Kim K.W.; Kim M.H.; Yu Y.S.; Intravenously administered gold nanoparticles pass through the blood-retinal barrier depending on the particle size, and induce no retinal toxicity. Nanotechnology 2009,20(50)

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PREVALENCE OF TYPE 2 DIABETES AMONG TRIBAL POPULATION OF INDIA: A MULTI-CENTRIC CROSS-SECTIONAL STUDY;Journal of the National Medical Association;2024-01

2. Chitosan modified 5-fluorouracil nanostructured lipid carriers for treatment of diabetic retinopathy in rats: A new dimension to an anticancer drug;International Journal of Biological Macromolecules;2023-01

3. Formulation development, characterization and In Vitro evaluation of 5-fluorouracil loaded nanostructured lipid carriers;THE FOURTH SCIENTIFIC CONFERENCE FOR ELECTRICAL ENGINEERING TECHNIQUES RESEARCH (EETR2022);2023

4. Role of novel drug delivery systems in overcoming the challenges associated with intraocular delivery of drugs;Multifunctional Nanocarriers;2022